Author : adminDate : 2021-09-02 12:30

HLB to present results of rivoceranib at global lung cancer meeting

HLB said the company would present the two interim results of combination treatment of its rivoceranib with immune-oncology and cytotoxic antineoplastic drugs at the online World Conference on Lung Cancer (WCLC) 2021 on Sept. 13. 

Please refer to the following website for further details: https://www.koreabiomed.com/news/articleView.html?idxno=12058